Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $132,471.50 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 5,407 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total value of $132,471.50. Following the sale, the insider directly owned 60,612 shares in the company, valued at $1,484,994. This trade represents a 8.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Filip Janku also recently made the following trade(s):

• On Monday, June 29th, Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $22.95, for a total value of $137,700.00.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total value of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Stock Performance

Shares of Monte Rosa Therapeutics stock opened at $24.21 on Friday. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -16.36 and a beta of 1.56. The company’s 50-day moving average price is $19.37 and its 200-day moving average price is $18.88.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. On average, sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wells Fargo & Company cut their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. increased their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Guggenheim boosted their target price on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and an average price target of $33.33.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter worth $30,000. Russell Investments Group Ltd. bought a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth $32,000. Lazard Asset Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after acquiring an additional 776 shares in the last quarter. 79.96% of the stock is currently owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.